United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $851,292.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $236.47, for a total transaction of $851,292.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,741.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Price Performance

UTHR opened at $237.00 on Thursday. The company has a market capitalization of $11.15 billion, a price-to-earnings ratio of 11.95 and a beta of 0.52. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $232.93 and a 200-day moving average price of $228.74. United Therapeutics Co. has a twelve month low of $204.44 and a twelve month high of $261.54.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping the consensus estimate of $4.28 by $0.08. The firm had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company’s revenue was up 25.1% on a year-over-year basis. During the same quarter last year, the company earned $2.67 earnings per share. Equities analysts expect that United Therapeutics Co. will post 23.76 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently bought and sold shares of the company. Blue Trust Inc. grew its stake in United Therapeutics by 10.0% during the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 46 shares in the last quarter. Formidable Asset Management LLC grew its stake in United Therapeutics by 1.5% during the third quarter. Formidable Asset Management LLC now owns 3,636 shares of the biotechnology company’s stock valued at $821,000 after acquiring an additional 53 shares in the last quarter. Alaska Permanent Fund Corp grew its stake in United Therapeutics by 1.7% during the third quarter. Alaska Permanent Fund Corp now owns 3,330 shares of the biotechnology company’s stock valued at $752,000 after acquiring an additional 57 shares in the last quarter. MBM Wealth Consultants LLC grew its stake in United Therapeutics by 2.7% during the first quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock valued at $515,000 after acquiring an additional 59 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in United Therapeutics by 1.6% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company’s stock valued at $856,000 after purchasing an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on UTHR. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and increased their target price for the company from $213.00 to $215.00 in a report on Monday, February 12th. HC Wainwright restated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. SVB Leerink initiated coverage on shares of United Therapeutics in a report on Monday, February 5th. They set an “outperform” rating and a $330.00 price objective for the company. Finally, StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $294.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.